evening, good and Mark, everyone. Slide Thanks, to turn X. Please
the Anika, is continues halfway dynamic now light in to up return things more to of all begin to to faced throw shaping as even during pandemic. feel the even transformative be are challenges can through like to normal year a curve We what we’ve starting for a X,XXX balls. successful COVID It’s
marketing to during restrictions shows conferences. to efforts teams up Anika’s and our begin and ramp COVID growing to sales promote quarter, As at product trade and portfolio the ease continue brand
teams Our surgeons directly products. we our engaging and and use training of in-person safe as the have increased have effective also been
joint of and the early as active the in engagement orthopedic proposition on story care. previously first focused view communicate to for the they direct value I transforming surgeons, opportunity meaningful solutions now patients, our off preservation, Anika as as return We’re a that seeing paying tremendous describe that we of signs living. provides who is their were unaware can portfolio this so see and our this treat new intervention to is continuum them Anika
variant rolling healthcare spike remaining however, COVID, and are, the world. with especially around the the the delta on to of systems We in impact respect its U.S. with cautious the and
adjusted double-digit EBITDA temporarily. shutting we Even confident elective in can on of XXXX certain procedures positive that hospital are cash growth down week, U.S. our that and deliver with mind, operating targets this Just reported flows. this it’s positive with being systems we’re revenue
We even and quarter early strategy we’re performance are also pleased this in with still good we very our multi-year with where though our in this are feel journey.
last into Let due XXXX business. me the quarter and quarter joint second year start with of by greatly some the its outlook. COVID reviewing and quarter go comparison Mike the will over favorable and year revenue to The our the review details last financial impacted was from our highlights growth some when and ended at was preservation QX the up to then XX% worst restoration
despite on and procedure year. of see the injection preservation to up levels XX% revenue with launch pre-COVID recovery to Joint continue We’re we our growth product half commercial year and in volumes execution. integration at now progress access strong strong into seeing headwinds XX% last expect of and on average market surgical second transformation, and over around the showed COVID restoration make and we focusing
patterns last business of X% joint Our to up of impact extended second last the pain COVID noting not management recovery initial in from COVID, full year. ordering that was QX, on half but into due was the customer year
positive With the with on are adjusted EBITDA operating cash above for pain ended million joint cash management The we we discuss for gross year profitability sheet. attractive remains Anika Mike has with over balance and the our outlook margins quarter the largely or as and believe $XX stabilized quarter with recovery we the business of this will of translating in in you our and targets XX% the equation year-to-date, to flow for revenue section. adjusted our year, at raising positive his
creation. along shareholder during profitability described growth our opportunity us we and Day, from set healthy revenue Investor will As Anika’s double-digit June apart for peers in tremendous our with value provide
by some first quarter the Wise WristMotion surgery Dr. Peter limited second successfully end marked initiated implant with total-wrist of the we completing Island, in University XX. was Arnold quarter, market significant Orthopedics launch on of the At business. the the our of of Rhode The milestones June for also
debilitating and joint native more patient both motion Wrist sides was As modular a preserve FDA wrist the patients carpal be treated pain arthritis radial most free into the a a better motion the are. incredibly that have deserve fusion, with solution. still preservation motion cleared very differentiated Considering meaning and painful and that arthritis wrist mimic postoperatively, limited and core the at risk preserving motion the risk is last anatomy. total system of they we reminder, restoring natural is by is October think can system of we joint who with replaces to
about the excited as We’re march full product we launch in in early interest September. this market toward
entering foundational clearance reverse clearance for shoulder step shoulder and reverse system expansion large and fast-growing in the also We a received in and the towards portfolio market. future for our during sets the first quarter. the stage for the XXX(k) This of development shoulder implant the Anika
to within After the medicine regulatory surgeons solutions. Arthroscopy is year awareness joint sports assuming their and to with As enabled delay able we them close XXXX. Society conference Medicine regenerative the don’t product-specific to and to be as focus this and combined bone quarter, of I’ve of of in a attended of out and the for quarter for joint preservation story at our subsequent is and Arthrosurface solutions of in on coming-out achieving presence booth at well and end, meaningful see product preserving $XX increasing Anika recently as opportunity in the to its as the with important trade able Sports orthopedic America happened the the million a to seeing result attended surgeons party will North was attend, we AAOS, to how excitement and in were well surgeon and The person, community, at the a Anika begin acquisition personally dynamics of Orthopedic training. meeting conference industry their earn show in which engage been number conference our be highlighting first the the also agreement. person needs around Association and milestone summer our unmet paid and meet portfolio with further of thrilled the Surgeons, for Nashville. addressing expanded I our of be major The American the Academy next COVID in in American event patients. of the great accordance end Orthopedic trade an Anika
Some plus Tactoset events such and implant. of our stemless shoulder anatomic surgeon highlights include brands promotional product OVOMotion are core as as plans Glenoid well key as Inlay an training around
quarter, development progress product Before I Mike review financials the X. to for our take our Slide to to like a review call I’d over turn on the to minutes more few
of regenerative solution, healing well including set fractures in time. the enhanced characteristics, As the full this the I June September took with to seeing Tactoset, US. truly year. first on HAA is total-wrist Surgeons described demand with earlier, better we and steps advantages, launching platform our in its in are first very growing doing for ability, treat market track launch performed our and surgery flow insufficiency
are later plans year. expansion an this Our additional for for track Tactoset XXX(k) on
our our in HYALOFAST enrollment CINGAL. We cartilage repair second-generation continue both for product single-stage clinical solutions OA studies pain and
updates trial as clinical two progresses provide will these as turn on Slide focused into now Please U.S. exciting the We to market. products bringing we enrollment X. remain
in the phase, Day taking us commercial systems, strong to the are scale commercial making Arthrosurface processes our Anika described is acquisitions XXXX we’re innings going June, place in investments We I early to and allow in Parcus, putting our As transformation people, strategy. and drive during see team, the Investor and growth. of multi-year and two a of in integrating through team the that
new we’ll geographic continue products our and into commercial are to continue focused preservation into the expand on to and move XXXX, As we’ll and that center areas. we ambulatory capabilities launch XXXX joint strengthen call point surgery and additional
for CINGAL the them States. to clinical by add time endgame as We and product the of trials is will profitability growth and this our is XXXX, that in also, drive beginning we in just existing no the portfolio. bring accelerated and through truly market to XXXX the and the continue investing I and through would in HYALOFAST expansion means period Anika United
technology is company on we X, excited Anika with why and Slide gross can you that have to on see two confident larger XXXX we about right times profitability. the we and and top a the future shareholder value. So the margins will remain very that line strong talent be drive remain by
around organization innovative We’re people with world a and J&J market billion our help strategy restoration one market strong the business, preservation of restore with keenly joint Mitek living. and commercial opportunity, position to our $X number U.S. active our for an pipeline the viscosupplement focused marketing products robust U.S. in partner, as on
Now, I’ll details over quarter. to the review turn of to the call the Mike
